» Articles » PMID: 35267606

Monocarboxylate Transporters Are Involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 10
PMID 35267606
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a five-year survival rate of <8%. PDAC is characterised by desmoplasia with an abundant extracellular matrix (ECM) rendering current therapies ineffective. Monocarboxylate transporters (MCTs) are key regulators of cellular metabolism and are upregulated in different cancers; however, their role in PDAC desmoplasia is little understood. Here, we investigated MCT and ECM gene expression in primary PDAC patient biopsies using RNA-sequencing data obtained from Gene Expression Omnibus. We generated a hypernetwork model from these data to investigate whether a causal relationship exists between MCTs and ECMs. Our analysis of stromal and epithelial tissues (n = 189) revealed nine differentially expressed MCTs, including the upregulation of SLC16A2/6/10 and the non-coding SLC16A1-AS1, and 502 ECMs, including collagens, laminins, and ECM remodelling enzymes (false discovery rate < 0.05). A causal hypernetwork analysis demonstrated a bidirectional relationship between MCTs and ECMs; four MCT and 255 ECM-related transcripts correlated with 90% of the differentially expressed ECMs (n = 376) and MCTs (n = 7), respectively. The hypernetwork model was robust, established by iterated sampling, direct path analysis, validation by an independent dataset, and random forests. This transcriptomic analysis highlights the role of MCTs in PDAC desmoplasia via associations with ECMs, opening novel treatment pathways to improve patient survival.

Citing Articles

Expression of nuclear receptors and glucose metabolic pathway proteins in sebaceous carcinoma: Androgen receptor and monocarboxylate transporter 1 have a key role in disease progression.

Choi Y, Yang M, Kim N, Khwarg S, Choung H, Kim J Oncol Lett. 2024; 28(6):593.

PMID: 39421321 PMC: 11484244. DOI: 10.3892/ol.2024.14726.


Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors.

Liao B, Wang J, Yuan Y, Luo H, Ouyang X Cancer Cell Int. 2024; 24(1):122.

PMID: 38555465 PMC: 10981830. DOI: 10.1186/s12935-024-03285-6.


Exploring monocarboxylate transporter inhibition for cancer treatment.

Koltai T, Fliegel L Explor Target Antitumor Ther. 2024; 5(1):135-169.

PMID: 38464385 PMC: 10918235. DOI: 10.37349/etat.2024.00210.


Cell-Biomaterial Interactions.

Deplaigne V, Rochefort G Bioengineering (Basel). 2023; 10(2).

PMID: 36829735 PMC: 9952813. DOI: 10.3390/bioengineering10020241.

References
1.
Chen J, Liu T, Peng H, Wu Y, Zhang L, Lin X . Up-regulation of Wnt7b rather than Wnt1, Wnt7a, and Wnt9a indicates poor prognosis in breast cancer. Int J Clin Exp Pathol. 2020; 11(9):4552-4561. PMC: 6962957. View

2.
Bardeesy N, DePinho R . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2(12):897-909. DOI: 10.1038/nrc949. View

3.
Lee G, Kim D, Chung M, Chae S, Kim H, Chae H . Lysyl oxidase-like-1 enhances lung metastasis when lactate accumulation and monocarboxylate transporter expression are involved. Oncol Lett. 2012; 2(5):831-838. PMC: 3408044. DOI: 10.3892/ol.2011.353. View

4.
Cheng X, Sato N, Kohi S, Yamaguchi K . Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS One. 2013; 8(11):e80765. PMC: 3823618. DOI: 10.1371/journal.pone.0080765. View

5.
Zhu J, Wu J, Pei X, Tan Z, Shi J, Lubman D . Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma. PLoS One. 2017; 12(4):e0175039. PMC: 5378402. DOI: 10.1371/journal.pone.0175039. View